Multiple Ascending Doses of MEDI6012 in Subjects With Stable Atherosclerotic Cardiovascular Disease

Participants received 3 doses of 40 milligram (mg) MEDI6012 IV on Days 1, 8, and 15.

Participants received 3 doses of placebo matching with MEDI6012 intravenously (IV) on Days 1, 8, and 15.

Participants received 3 doses of 120 mg MEDI6012 IV on Days 1, 8, and 15.

Participants received 3 doses of 300 mg MEDI6012 IV on Days 1, 8, and 15.

Participants received 3 doses of placebo matching with MEDI6012 by IV push. A loading dose on Day 1 and maintenance doses on Days 3 and 10.

Participants received 3 doses of MEDI6012 by IV push as 300 mg loading dose on Day 1, and maintenance doses of 150 mg and 100 mg on Day 3 and Day 10, respectively.